Live
- From breast cancer to brain, DNA damage - here's how ethylene oxide can affect your health
- EPFO adds 15.48 lakh net members in February as employment rises
- What's wrong if Rahul Gandhi contests from two places, Modi did it too: KC Venugopal
- Red Cross ambulatory medical services for the elderly in Lingasanipalli village
- Varun Sandesh comes with a concept-based film ‘Nindha’
- Priyadarshi’s rom-com with Nabha Natesh titled ‘Darling’
- Vedhika captivates in a mesmerising Blue lehenga
- Director Tharun Bhascker ventures into lead role opposite Eesha Rebba
- Scary first look of Sunny Leone’s ‘Mandira’ unveiled
- Nara Rohith’s ‘Prathinidhi 2’ trailer promises gripping political drama
Woman From America Totally Recovered From HIV
Woman From America Totally Recovered From HIV
- The patient is a member of an exceptionally small group of people who appear to have completely eradicated the virus from their systems.
- Only two previous examples of entire HIV remission have ever been adequately validated, both following leukaemia therapy with bone marrow transplants from donors carrying HIV-blocking mutations.
An unknown American woman was diagnosed with HIV ten years ago. She faced a lifetime of anti-retroviral therapy to protect the virus from exterminating her immune system, just like the tens of thousands of people who test positive in the United States each year.
That is not the only way to suffer, now it has a solution. The patient is a member of an exceptionally small group of people who appear to have completely eradicated the virus from their systems. Furthermore, the means by which she was cured gives hope to scores of other people each year.
The virus-free middle-aged patient was previously reported by a team of researchers in the United States working as part of the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) over than four years following a groundbreaking blood cancer treatment.
Only two previous examples of entire HIV remission have ever been adequately validated, both following leukaemia therapy with bone marrow transplants from donors carrying HIV-blocking mutations.
One of them, a Caucasian man known as the patient from Berlin, had been in remission for more than a decade before succumbing to cancer in 2020. The other, a Latino man known as the patient from London has been clear of the infection for more than two years.
The woman at the centre of this recent case, like these two well-known individuals, was diagnosed with blood cancer. In 2017, examinations revealed that she had acute myelogenous leukaemia (AML), a life-threatening bone marrow disease.
Ashe woman had been 'White,' she would have had a better chance of finding a tissue match in the collection of willing donors, which is dominated by Caucasians. Because of her mixed-race background, doctors resorted to another source of stem cells umbilical cord blood to see if it may help her grow fresh, healthy bone marrow.
Unlike other tissue transplants, blood from a newborn's umbilicus does not necessitate a precise immunological match between the donor and the recipient. More than 35,000 leukaemia patients have obtained cord blood donation during the 1990s all around the world.
While cord blood is a popular treatment for AML, it requires weeks for it to establish in and create enough white cells to hold infections at bay. This renders it a terrible choice for anyone battling with a life-threatening infection.
The patient's medical team created a two-pronged method to overcome this problem: get blood infusions from a compatible relative to supply her with a temporary defence, and cord stem cells that can gradually generate white cells. As a benefit, the cord cells the patient obtained came with a special ability. The CCR5 delta-32 mutation was found in two copies of their DNA.
The expression of the CCR5 co-receptor, which most HIV strains employ to gain access into the body's cells, is altered by this minor genetic change. The virus won't be able to enter white blood cells and destroy them if it doesn't have simple access to them.
All of the person's T white blood cells and myeloid cells as white blood cells that swallow up invaders were formed from the stem cells in the cord blood three months after her transplant, not from her old marrow or her relative's blood.
That indicates they all had the protective variant of the CCR5 co-receptor, which effectively blocked her HIV. The patient hasn't taken any antiretroviral treatment since then, and there are no indicators of active HIV particles.
The experts reported their preliminary discoveries at the 2022 Conference on Retroviruses and Opportunistic Infections, but they have yet to report or make their findings public.
For the time being, the trial offers the enticing prospect of treating a fraction of the world's HIV patients which is an ongoing pandemic that currently affects over 40 million people worldwide. This isn't to say that this new therapy will be offered to all HIV-positive persons anytime soon. Because of the hazards, it's still just an option for treating life-threatening blood malignancies, with the possibility of curing HIV as a bonus.
